Multi-biomarker panel to predict prognosis and treatment response in intestinal acute graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will collect clinical, transplant and experimental biomarker data from patients aged 12 and older treated with allogeneic hematopoietic stem cell transplantation at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The focus is on intestinal acute graft-versus-host disease, with serial measurement of candidate blood and clinical biomarkers and linkage to treatment and outcome data. Researchers will integrate these data to develop and validate a predictive algorithm for prognosis and treatment response. No investigational therapies are given; the goal is to create a tool to guide personalized care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥ 12 years
* Indication for allogeneic HSCT
* Obtaining informed consent

Exclusion Criteria:

* None

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Bologna, Italy Recruiting

Study contacts

• Study coordinator: Giovanni Barbara, MD
• Email: giovanni.barbara@unibo.it
• Phone: +390512144103

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax

  This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07148180

• Telehealth music therapy for cognitive difficulties in blood cancer survivors

  This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07052916

• Personalized T cells engineered to target TP53 or RAS mutations in blood cancers

  This trial will try using a patient's own T cells, modified to recognize specific TP53 or RAS mutations, to treat adults with certain blood cancers.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06904066

• Pharmacogenomics to improve voriconazole dosing for fungal infections

  This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.

  Recruiting at 7 sites Phase 2 The University of Queensland · Seattle, Washington and 6 other locations · NCT06510699

• Effects of nutrient timing on cancer-related fatigue

  This study is testing if eating all meals within a 10-hour window can help cancer survivors with blood cancers feel less tired and improve their quality of life.

  Recruiting Phase 2 University of Maryland, Baltimore · Baltimore, Maryland · NCT06482515

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.